Faruqi & Faruqi Investigates Novo Nordisk Securities Class Action

Strategic Insights -

Investors who suffered losses in Novo Nordisk's stock between May 7 and July 28, 2025, are reminded of the September 30, 2025, deadline to seek lead plaintiff status in a federal securities class action. The complaint alleges that the company and its executives made false and misleading statements about Novo's growth potential, understating the impact of the compounded market exclusion and overstating the likelihood of patients switching to Novo's branded alternatives. Novo's stock price declined by 21.83% on July 29, 2025, after the company announced a sales and profit outlook downgrade due to market expansion and competition issues.

Key Takeaways:

  • Faruqi & Faruqi, LLP is investigating potential claims against Novo Nordisk A/S and its executives for violating federal securities laws.
  • The complaint alleges that the company understated the impact of the compounded market exclusion and overstated the likelihood of patients switching to Novo's branded alternatives.
  • Novo's stock price declined by 21.83% on July 29, 2025, after the company announced a sales and profit outlook downgrade.
  • The deadline to seek lead plaintiff status is September 30, 2025.
  • Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice.
  • The decision to serve as a lead plaintiff or not does not affect an investor's ability to share in any recovery.

Statistics:

  • The price of Novo's common stock declined from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025.
  • The decline represents a 21.83% loss in a single day.
  • The complaint alleges that Novo's executives made false and/ or misleading statements about the company's growth potential between May 7, 2025, and July 28, 2025.
  • The deadline to seek lead plaintiff status is September 30, 2025.

Sources:

  • Newsfile Corp., "Faruqi & Faruqi, LLP Investsigating Novo Nordisk Securities Class Action," August 19, 2025
  • Faruqi & Faruqi, LLP website, www.faruqilaw.com (n.d.)
  • LinkedIn, X, Facebook (n.d.)